What is BRTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BRTX?

P/E (TTM) is n/a and 52-week range is $2.01 to $34.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BRTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BRTX?

The company profile lists revenue (TTM) near $10M, net income (TTM) near $-31.78B, EPS (TTM) near $-15.98 when available from the market-data feed. Figures are informational and may lag live markets.

Where is BioRestorative Therapies Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Melville, New York, US, 25.5M shares outstanding, ISIN US0906556065 when available from company profile and filing metadata.

BioRestorative Therapies Inc

$BRTX

Health Care · Biotechnology

IR Run Scenarios

$1.91

+1.06%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 13 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.

Employees

Website

www.biorestorative.com/

IPO

2001-07-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)